ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
3 announcements with these filters
NATCO reported Q1 FY27 consolidated revenue of INR 794.4 Cr and PAT of INR 206.5 Cr. Performance was driven by base business growth and a strong flu season at associate Adcock Ingram.
Natco reported a sharp revenue decline due to lower Revlimid contributions, masked by strong growth in Brazil and domestic segments.
Natco Pharma reported Q1 FY27 revenue of INR 7,944 Mn and Net Profit of INR 2,065 Mn. Strategy focuses on high-barrier US formulations and NCE/Cell & Gene therapy investments.